Systemic pigmentation from tetracycline and minocycline therapy

White, Stacy

doi:10.1001/archderm.119.1.1

Cited by 43 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One patient had an irreversible cutaneous pigmentation attributable to doxycycline use. 18 No diarrhea or joint pain was reported. The patient who died was still receiving antibiotic drug treatment when he had a valvular replacement and died postoperatively of car-diac incompetency.…”

mentioning

confidence: 99%

Treatment of Q Fever Endocarditis

Raoult

Houpikian²,

Dupont³

et al. 1999

Arch Intern Med

302

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Treatment of Q Fever Endocarditis

Raoult

Houpikian²,

Dupont³

et al. 1999

Arch Intern Med

302

View full text Add to dashboard Cite

show abstract

“…Those affected may manifest one or more of these pigmentary responses 19,20 , 26,30 , 32 . What is described as Type I is observed at localized sites of inflammation and trauma, including contusions, ulcerations, lacerations, and within existing scars, including those associated with acne 19–23,27 , 30,32–34 (Fig. 6).…”

Section: Discussionmentioning

confidence: 99%

Persistent post‐sclerotherapy pigmentation due to minocycline. Three cases and a review of post‐sclerotherapy pigmentation

Green

2002

J of Cosmetic Dermatology

View full text Add to dashboard Cite

This is the first report of such minocycline-aggravated post-sclerotherapy pigmentation. Persistent post-sclerotherapy pigmentation caused by minocycline is a risk associated with ingestion of this drug. Patients need to be warned of this risk because, unlike post-sclerotherapy pigmentation that develops in the absence of drug ingestion, minocycline-aggravated post-sclerotherapy pigmentation may persist for years.

show abstract

“…The incidence of postsclerotherapy hyperpigmentation seems to be a result of multiple factors, including sclerosing solution and treatment technique. It has been reported in 11-80% of patients treated with STS, [11][12][13] 10-30% of those treated with HS, [13][14][15][16][17] and 7-30% when POL is used as the sclerosing solution. 18,19 Hemosiderin is a protein produced by the phagocytic digestion of hematin.…”

Section: Discussionmentioning

confidence: 99%